Clinical trials: Carcinoma;Endocrine
Carcinoma, Pancreatic Ductal
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer.
- Trial name
- NCT05723978
- Testing
- Selective extended dissection of pancreaticoduodenectomy
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
This randomized phase II trial is studying mitotane and IMC-A12 to see how well they work compared with mitotane alone in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by…
- Conditions
- Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
- Trial name
- NCT00778817
- Testing
- IMC-A12, mitotane
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Neoplasm Metastasis
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
- Conditions
- Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma
- Trial name
- NCT00116389
- Testing
- talabostat mesylate tablets, gemcitabine
- Where
- 28 sites in United States
- Volunteers
- 60 people
- Sponsor
- Point Therapeutics
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Soft-tissue Sarcoma, Triple Negative Breast Cancer
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small…
- Conditions
- Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT07064018
- Testing
- Spedox-6, Pegfilgrastim, Filgrastim
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, Irvine
Endometrioid Adenocarcinoma, Serous Carcinoma
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
Advanced technology has enabled radiation oncologists to more accurately and precisely target radiation to areas at risk while maximally sparing healthy tissue.
- Conditions
- Endometrioid Adenocarcinoma, Serous Carcinoma, Clear Cell Carcinoma, Carcinosarcoma
- Trial name
- NCT04458597
- Testing
- Image-guided adjuvant pelvic radiotherapy
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
The aim of the study is to evaluate the efficacy of the combination of lenvatinib with pembrolizumab, and to establish a safe and effective systemic treatment regimen for patients with metastatic anaplastic thyroid cancer (ATC) /…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage
- Trial name
- NCT04731740
- Testing
- Lenvatinib, Pembrolizumab, Chemotherapy
- Where
- Russia
- Sponsor
- Saint Petersburg State University, Russia
Genital Diseases, Female, Ovarian Diseases
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer
The purpose of this study is to determine whether the early and continuous addition of bevacizumab for up to 30 months to the standard chemotherapy is more effective than the early and continuous addition of bevacizumab for up to…
- Conditions
- Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- BOOST (NCT01462890)
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 131 sites in Denmark, Finland and 4 more
- Volunteers
- 927 people
- Sponsor
- AGO Study Group
Carcinoma, Islet Cell, Carcinoma, Pancreas
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received…
- Trial name
- NCT00428597
- Testing
- sunitinib malate
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Pfizer
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Solid Tumor, Thyroid Cancer
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors.
- Trial name
- NCT00354523
- Testing
- Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Multi-center, phase III trial of DCVAC/OvCa added to standard of care treatments for relapsed ovarian cancer. Patients will receive study treatment until all doses are administered, or other criteria are met.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- VITALIA (NCT03905902)
- Testing
- DCVAC/OvCa
- Sponsor
- SOTIO a.s.
Non Endometrioid Carcinoma, Endometrioid Carcinoma
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
The aim of this trial is to evaluate the sentinel node policy in early stage endometrial carcinomas at intermediate and high risk of recurrence (by comparing the sentinel node policy to current initial staging protocols).
- Trial name
- SENTIRAD (NCT02598219)
- Testing
- Pre-operative SN mapping with radionucleide, Intra-operative SN mapping with patent V blue dye, Intra-operative SN mapping with indocyanin green
- Where
- 16 sites in France
- Volunteers
- 262 people
- Sponsor
- Centre Oscar Lambret
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Neoplasms, Digestive System Neoplasms
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared…
- Conditions
- Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- apact (NCT01964430)
- Testing
- nab-Paclitaxel, Gemcitabine
- Where
- 341 sites in United States, Australia and 19 more
- Volunteers
- 866 people
- Sponsor
- Celgene
Papillary Thyroid Carcinoma, Lymph Node Cancer Metastatic
Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma
Establish a predictive model for assessing neck lymph node metastasis of papillary thyroid carcinoma based on metabolomics, proteomics, and imaging omics data, exploring an ideal protocal for the precise diagnosis and treatment…
- Trial name
- NCT06725628
- Testing
- Thy_CLNM_multi_omics
- Volunteers
- 2,000 people
- Sponsor
- Tianhan Zhou
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00066729
- Testing
- NY-ESO-1 peptide vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Fallopian Tube Cancer
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- NCT00582205
- Testing
- Paclitaxel, Cisplatin IP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.